{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:12:45Z","timestamp":1793419965320,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"the San Luis Obispo County Community Foundation"},{"name":"the Singing Field Foundation"},{"DOI":"10.13039\/100000738","name":"the Department of Veterans Affairs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.parkreldis.2015.02.020","type":"journal-article","created":{"date-parts":[[2015,2,28]],"date-time":"2015-02-28T07:59:09Z","timestamp":1425110349000},"page":"500-503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration in Parkinson's disease"],"prefix":"10.1016","volume":"21","author":[{"given":"Maya","family":"Katz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Joon","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngja","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean P.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond A.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham A.","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2015.02.020_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.freeradbiomed.2013.05.001","article-title":"Glutathione metabolism and Parkinson's disease","volume":"62","author":"Smeyne","year":"2013","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.parkreldis.2015.02.020_bib2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ana.410350107","article-title":"Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease","volume":"35","author":"Dexter","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2015.02.020_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1600-0404.1993.tb00013.x","article-title":"Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease","volume":"146","author":"Jenner","year":"1993","journal-title":"Acta Neurol Scand Suppl"},{"issue":"2","key":"10.1016\/j.parkreldis.2015.02.020_bib4","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1471-4159.1989.tb09150.x","article-title":"Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains","volume":"52","author":"Riederer","year":"1989","journal-title":"J\u00a0Neurochem"},{"issue":"3","key":"10.1016\/j.parkreldis.2015.02.020_bib5","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ana.410360305","article-title":"Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia","volume":"36","author":"Sian","year":"1994","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.parkreldis.2015.02.020_bib6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.biopha.2008.01.017","article-title":"Glutathione and Parkinson's disease: is this the elephant in the room?","volume":"62","author":"Zeevalk","year":"2008","journal-title":"Biomed Pharmacother"},{"issue":"5\u20136","key":"10.1016\/j.parkreldis.2015.02.020_bib7","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0006-2952(02)01174-7","article-title":"Glutathione, iron and Parkinson's disease","volume":"64","author":"Bharath","year":"2002","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.parkreldis.2015.02.020_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1254\/jphs.08R01CR","article-title":"Regulation of neuronal glutathione synthesis","volume":"108","author":"Aoyama","year":"2008","journal-title":"J\u00a0Pharmacol Sci"},{"issue":"8","key":"10.1016\/j.parkreldis.2015.02.020_bib9","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1016\/j.bbagen.2013.04.016","article-title":"The chemistry and biological activities of N-acetylcysteine","volume":"1830","author":"Samuni","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.parkreldis.2015.02.020_bib10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nn1609","article-title":"Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse","volume":"9","author":"Aoyama","year":"2006","journal-title":"Nat Neurosci"},{"issue":"3","key":"10.1016\/j.parkreldis.2015.02.020_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ana.22162","article-title":"N-acetylcysteine prevents loss of dopaminergic neurons in the EAAC1\u2212\/\u2212 mouse","volume":"69","author":"Berman","year":"2011","journal-title":"Ann Neurol"},{"issue":"7\u20138","key":"10.1016\/j.parkreldis.2015.02.020_bib12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.nut.2007.05.004","article-title":"Antioxidative and anti-inflammatory effects of four cysteine-containing agents in striatum of MPTP-treated mice","volume":"23","author":"Chen","year":"2007","journal-title":"Nutrition"},{"issue":"8","key":"10.1016\/j.parkreldis.2015.02.020_bib13","doi-asserted-by":"crossref","first-page":"e12333","DOI":"10.1371\/journal.pone.0012333","article-title":"Oral N-Acetyl-cysteine attenuates loss of dopaminergic terminals in \u03b1-synuclein overexpressing mice","volume":"5","author":"Clark","year":"2010","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.parkreldis.2015.02.020_bib14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.neulet.2004.03.072","article-title":"Preventive effect of antioxidants in MPTP-induced mouse model of Parkinson's disease","volume":"363","author":"Park","year":"2004","journal-title":"Neurosci Lett"},{"issue":"1","key":"10.1016\/j.parkreldis.2015.02.020_bib15","first-page":"48","article-title":"Attenuation of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine induced nigrostriatal toxicity in mice by N-acetyl cysteine","volume":"53","author":"Sharma","year":"2007","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"3","key":"10.1016\/j.parkreldis.2015.02.020_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tips.2013.01.001","article-title":"The promise of N-acetylcysteine in neuropsychiatry","volume":"34","author":"Berk","year":"2013","journal-title":"Trends Pharmacol Sci"},{"issue":"8","key":"10.1016\/j.parkreldis.2015.02.020_bib17","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1212\/WNL.57.8.1497","article-title":"Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease","volume":"57","author":"Hughes","year":"2001","journal-title":"Neurology"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.parkreldis.2015.02.020_bib18","first-page":"664","article-title":"Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration: phase I trial in Parkinson's disease [abstract]","volume":"29","author":"Katz","year":"2014","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.parkreldis.2015.02.020_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/WNF.0b013e31829ae713","article-title":"N-acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases","volume":"36","author":"Holmay","year":"2013","journal-title":"Clin Neuropharmacol"},{"issue":"1 Suppl.\u00a01","key":"10.1016\/j.parkreldis.2015.02.020_bib20","first-page":"76","article-title":"Clinical safety of high oral doses of acetylcysteine","volume":"10","author":"Miller","year":"1983","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.parkreldis.2015.02.020_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mehy.2012.03.021","article-title":"N-acetyl-cysteine in the treatment of Parkinson's disease. What are we waiting for?","volume":"79","author":"Mart\u00ednez-Banaclocha","year":"2012","journal-title":"Med Hypotheses"},{"issue":"1","key":"10.1016\/j.parkreldis.2015.02.020_bib22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0006-8993(00)02005-9","article-title":"N-acetylcysteine elicited increase in complex I activity in synaptic mitochondria from aged mice: implications for treatment of Parkinson's disease","volume":"859","author":"Mart\u0131\u0301nez-Banaclocha","year":"2000","journal-title":"Brain Res"},{"issue":"5","key":"10.1016\/j.parkreldis.2015.02.020_bib23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","article-title":"A\u00a0randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit","volume":"71","author":"Parkinson Study Grop QE3 Investigators","year":"2014","journal-title":"JAMA Neurol"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802015000759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802015000759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T02:16:50Z","timestamp":1651371410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802015000759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S1353802015000759"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2015.02.020","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2015.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}